Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths, signed a commercial supply agreement with Catalent for the manufacture of Harm Reduction Therapeutics’ naloxone nasal spray, RiVive (3.0 mg), for the emergency treatment of known or suspected opioid overdose.   The commercial supply agreement comes after the U.S. FDA granted Priority Review status on December 26, 2022, for the over-the-counter (OTC) naloxone nasal spra...